Indication : 

• The treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy
• The treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.

Compositions :

Each vial contain Bortezomib 3.5 mg

Storage Condition : 

When reconstituted as directed, Bortezomib may be stored at 25°C. Reconstituted Bortezomib should be administered immediately or may be stored for 8 hours under indoor lighting. 

Unopened vials may be stored at below 30°C. Shelf life 24 months.

Shelf Life :